Video

Dr. Broghammer on patient selection for treatment with intracavernosal injections

Author(s):

Urology Times staff
Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
    • Chapters
    • descriptions off, selected
    • captions off, selected

      Joshua A. Broghammer, MD, discusses the ideal patient population for treatment with intracavernosal injections for erectile dysfunction. Broghammer is an associate professor of Urology at the University of Kansas Medical Center.

      Related Videos
      Experts consider efficacy of fertility restoration vs sperm cryopreservation
      Experts consider efficacy of fertility restoration vs sperm cryopreservation
      Matthew Mutter, MD, shares data on Separo vessel sealing system for vasectomy
      Matthew Mutter, MD, shares data on Separo vessel sealing system for vasectomy
      Fertility restoration may offer benefits in cost, efficacy vs sperm cryopreservation
      Fertility restoration may offer benefits in cost, efficacy vs sperm cryopreservation
      Investigators discuss cost-effectiveness study of cryopreservation vs vasectomy reversal
      Investigators discuss cost-effectiveness study of cryopreservation vs vasectomy reversal
      Justin Dubin, MD, answers a question during a video interview
      Justin Dubin, MD, on potential health effects of SARMs and anabolic steroids
      Man talking with a doctor | Image Credit: © RFBSIP - stock.adobe.com
      Study identifies trends in testosterone use in young adult men
      Kristy L. Mardis, NP, on APP development initiatives in sexual medicine
      Kristy L. Mardis, NP, on APP development initiatives in sexual medicine
      Dr. Nam on potential future research on vasectomy in the post-Dobbs era
      Dr. Nam on potential future research on vasectomy in the post-Dobbs era
      Dr. Nam on the increased interest in vasectomy amidst urologist shortages
      Dr. Nam on the increased interest in vasectomy amidst urologist shortages
      Dr. Rust recaps the SMSNA Men’s Health Fellowship Bootcamp
      Dr. Rust recaps the SMSNA Men’s Health Fellowship Bootcamp
      Related Content
      Study links poor semen quality with shorter life span
      March 5th 2025

      Study links poor semen quality with shorter life span

      Hannah Clarke
      The average life expectancy was 80.3 years among men with a total motile sperm count over 120 million, compared with 77.6 years among men with a total motile sperm count ranging from >0 to 5 million.
      Dr. Bristol Whiles discusses her experience as a urology resident
      July 25th 2022

      Dr. Bristol Whiles discusses her experience as a urology resident

      Kansas University Department of Urology
      On this podcast, Bristol Whiles, MD, discusses her urology residency experience at the Kansas University School of Medicine Department of Urology.
      US FDA logo in white over a blue background. | Credit: US Food and Drug Administration
      February 4th 2025

      FDA Updates in Urology: January 2025

      Patrick Campbell
      A recap of the FDA submissions and regulatory decisions in urology from January 2025.
      The urologist's role in dispelling men's health myths
      May 10th 2022

      The urologist's role in dispelling men's health myths

      Urology Times staff
      “I think it's really important to understand the role of prevention and early detection,” says Michael Lutz, MD.
      FDA clears chemiluminescence-based immunoassay for free testosterone
      January 10th 2025

      FDA clears chemiluminescence-based immunoassay for free testosterone

      Hannah Clarke
      The test can provide results in 48 minutes for diagnostic insights for conditions such as hypogonadism, impotence, polycystic ovarian syndrome, and other androgenital syndromes.
      Men with severe ED more than twice likely to have high ceramide levels
      October 18th 2024

      Men with severe ED more than twice likely to have high ceramide levels

      Kevin Kunzmann
      New research better defines the link between cardiovascular disease risk and prevalence of ED per serum ceramide levels.
      © 2025 MJH Life Sciences

      All rights reserved.